Researchers investigated a biomimetic lipid nanocomposite delivery system combining methylene blue (the active agent) with a carrier component designed to address two hallmarks of Alzheimer’s disease pathology: amyloid-β accumulation and tau phosphorylation (in vitro and animal model studies). The nanocomposite demonstrated enhanced clearance of amyloid-β and reduced tau phosphorylation compared to methylene blue alone, suggesting synergistic effects from the drug-carrier combination. **Evidence level: Preclinical (in vitro and animal model).**
Read more on Advanced science (Weinheim, Baden-Wurttemberg, Germany) →